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Short Communication 
Trend analysis of lab tests requisitions of COVID-19 prognostic biomarkers 
at a clinical chemistry reference laboratory-an observational study 
Sibtain Ahmed, Farooq Ghani * 
Pathology and Laboratory Medicine, Aga Khan University, Stadium Road, Karachi, 74800, Pakistan   








A B S T R A C T   
Background: Biochemical parameters, such as C-reactive protein (C-RP), Procalcitonin (PCT), Lactate dehydro-
genase (LDH) and Ferritin are associated with COVID-19 severity and prognosis. This trend analysis of COVID-19 
prognostic biomarker requisitions is aimed at providing a reflection of the clinical practices adopted amidst the 
peak of the pandemic. This knowledge of the prognostic biomarkers utilized, will further aid to classify patients 
based on their risk, for optimal resource allocation and improve outcomes. 
Material & methods: This cross-sectional study was conducted at the clinical chemistry laboratory at the Aga Khan 
University Hospital (AKUH), Karachi Pakistan. A team consisting of two clinical chemistry consultants reviewed 
the COVID-19 prognostic biomarkers tests performance data from March to July 2020 using the integrated 
laboratory information management system (ILMS). The test statistics of March to July 2020 when COVID-19 
cases were on the rise in the country were compared with those of the same months from 2019. The changes 
in the test groups were expressed in percentages. Microsoft Excel for windows 2019 was used for data analysis. 
Results: The total specimens received for testing in 2020 (n = 574,092) showed a percent decline of approxi-
mately (− ) 33% compared to 2019 (n = 858,756). Contrary to the overall decline in volumes an upward surge 
was noted for the prognostic biomarkers. From March to July, the highest percent change was noted for LDH 
(+155.1%), followed by PCT (+66.7.1%), C-RP (+26.5%) and Ferritin (+22.1%) in 2020 compared to the same 
time frame in 2019. The highest percent change was noted in June. 
Conclusion: During the COVID 19 pandemic, a significant increase in utilization of laboratory services was seen 
for COVID-19 prognostic markers.   
1. Introduction 
The Coronavirus Disease 2019 (COVID-19) pandemic, a respiratory 
and systemic viral disease, caused by severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2), emerged on the global health scenario in 
late December 2019 and becoming a global pandemic in 2020 [1]. 
Clinical laboaratories have played a critical role in managing the 
pandemic [2]. Even though the clinical laboratories continued their 
operations 24/7, the lockdown and restrictions imposed by most coun-
tries to decrease the risk of contagion, have affected the course of routine 
medical services [3]. 
In this era of unprecedented health crisis, in addition to rapid and 
accurate diagnostic tests, the clinical laboratory specialists were in 
search for reliable biomarkers associated with COVID-19 disease pro-
gression, in order to stratify high risk subjects, particularly in resource 
constrained setups for optimal intensive care [4]. 
COVID-19 patients are classified into mild, moderate, severe, and 
critical disease [5]. Various studies have reported biochemical param-
eters, such as C-reactive protein (C-RP), Procalcitonin (PCT), Lactate 
dehydrogenase (LDH) and Ferritin to be associated with COVID-19 
severity and prognosis [3]. The increase in inflammation markers and 
acute phase reactants are linked with the underlying systemic vasculitic 
processes and the cytokine storm that cause most parenchymal lesions in 
vital organs [3]. 
On one end, amid the COVID-19 pandemic, the delay of non-urgent 
health services and subsequent decline in the number of patients due to 
concern of contagion, is expected to lead to a significant drop in the 
overall routine biochemical test requisitions, while on the other, a rapid 
surge in the test requests for the COVID-19 prognostic biomarkers is 
projected. At our institute, a tertiary care hospital in the metropolis of 
Karachi, during the lockdown and restrictions, all elective, semi-elective 
procedures and non-essential procedures were cancelled. From April to 
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June 2020, our pediatric surgery department, performed only one-third 
the volume compared to the preceding three months [6]. Moreover, the 
number of clinics in each specialty was cut down and tele-clinics were 
also introduced from beginning of April [7]. 
The aim of this study was to investigate the trend in COVID-19 
prognostic biomarkers requisitions including C-RP, PCT, LDH and 
Ferritin, at a high-volume clinical chemistry laboratory in Pakistan 
during the peak pandemic months. Furthermore, the test statistics of 
March to July 2020 when COVID-19 cases were on the rise were 
compared with those of 2019. While much was unknown about the 
course of COVID-19 disease, the clinicians utilized some of the lessons 
learnt from previous experiences and knowledge for prognostic 
biomarker selection. This trend analysis of COVID-19 prognostic 
biomarker requisitions is aimed at providing a reflection of the clinical 
practices adopted amidst the peak of the pandemic. This knowledge of 
the prognostic biomarkers utilized, will further aid to classify patients 
based on their risk, for optimal resource allocation and improve 
outcomes. 
2. Methods 
This retrospective observational study was conducted at the clinical 
chemistry laboratory at the Aga Khan University Hospital (AKUH), 
Karachi Pakistan, which serves as a national reference lab for the 
country. With its growing network of more than 260 phlebotomy centers 
and outreach laboratories spread across Pakistan, it caters to test re-
quests from all the provinces. The laboratory operates to highest stan-
dards of quality and was the first lab to be accredited by College of 
American Pathologists (CAP) as well as Joint Commission International 
Accreditation (JCIA). 
A team consisting of two clinical chemistry consultants reviewed the 
COVID-19 prognostic biomarkers tests performance data from March to 
July 2020 using the integrated laboratory information management 
system (ILMS). The test statistics of March to July 2020 when COVID-19 
cases were on the rise in the country were compared with those of the 
same months from 2019. 
Frequencies and percentages were analyzed for confirmed cases of 
covid-19, active cases of covid-19, deaths, recoveries, total specimen 
count and total prognostic biomarkers specimen count of 2019 and 2020 
respectively. The test requisition statistics of prognostic biomarkers 
volumes for March to July in 2019 and 2020 were compared; and the 
changes in the test groups were expressed in terms of percent change 
alongside its graphical representation. Microsoft Excel for windows 
2019 was used for data analysis. 
3. Results 
A descriptive detail of the total confirmed cases, active cases, deaths 
and recoveries according to the data collected by the Government of 
Pakistan alongside the change in total specimens received and the four 
prognostic biomarkers specimens received based on a comparison be-
tween 2019 and 2020 for the months from March to July is shown in 
Table 1 [8]. 
Furthermore, the total specimens received for testing in 2020 (n =
574,092) showed a percent decline of approximately (− ) 33% compared 
to 2019 (n = 858,756). Contrary to the overall decline in volumes an 
upward surge was noted for the prognostic biomarkers i.e. the total 
specimen volume received for testing in 2020 (n = 71,548) showed 
41.4% increase compared to 2019 (n = 50,601). In totality, from March 
to July, the highest percent change was noted for LDH (+155.1%), fol-
lowed by PCT (+66.7.1%), C-RP (+26.5%) and Ferritin (+22.1%) in 
2020 compared to the same time frame in 2019. The highest percent 
change was noted in June for all the biomarkers, the highest being LDH 
(+483.1) followed by Ferritin, PCT and C-RP respectively. 
On further stratification into monthly volumes, the percent change 
noted for these biomarkers in 2020 compared to 2019 is elaborated in 
Table 2. Fig. 1 presents a graphical depiction of trend analysis of the four 
prognostic biomarkers test volumes recorded in 2020 compared to the 
subsequent months in 2019. 
4. Discussion 
The test requisition data shows a general surge in the four prognostic 
biomarkers utilization amid the COVID-19 pandemic. This study depicts 
that PCT demonstrated a positive trend right from March 2020 
compared to the other three biomarkers, which were initially lower 
compared to 2019 in March and April. PCT is an established biomarker 
to differentiate bacterial from viral infections, and a meta-analysis re-
ported a ~5-fold higher risk of severe COVID-19 infection associated 
with elevated PCT [9,10]. However, a paradigm shift was observed in 
May 2020 when a steady increase in test requests was noted for all the 
four biomarkers. 
This variation in trend could be linked to several reasons, for instance 
May 2020 was regarded as the month when the cases of COVID-19 
exhibited a rapid upheave in Pakistan [11]. Additionally, the strict 
lockdown imposed in late March restricted patient movements leading 
to a decline in test volumes, which gradually improved as the re-
strictions were subsequently relaxed in the following months beginning 
around May 10, 2020 [12]. Additionally, the hospital to which the 
Table 1 
COVID-19 cases in Pakistan and the trend of change in total number of specimens and prognostic biomarkers specimens’ data of March to July 2020 compared to same 
time period in 2019.  
Months Confirmed Cases of 
COVID-19 (n) 







count 2019 (n) 
Total Specimen 







March 2039 1931 26 82 188,710 125,321 11,028 7600 
April 16,817 12,117 385 4315 192,966 81,574 10,813 7679 
May 72,460 44,834 1543 26,083 153,898 95,857 9622 11,366 
June 213,470 108,273 4395 100,802 146,784 132,017 8787 25,602 
July 279,146 25,149 5970 248,027 176,398 136,323 10,351 19,301  
Table 2 
Percent change in COVID-19 prognostic biomarkers volumes for March to July 
in 2019 and 2020.   
C-RP LDH PCT Ferritin 
March 2019 (n) 5935 974 1199 2920 
March 2020 (n) 4069 687 1292 1552 
Change (%) − 31.4 − 29.5 +7.8 − 46.8 
April 2019 (n) 5680 948 1011 3174 
April 2020 (n) 3648 1115 1226 1690 
Change (%) − 35.8 +17.6 +21.3 − 46.8 
May 2019 (n) 4944 894 1026 2758 
May 2020 (n) 5238 1743 1603 2782 
Change (%) +5.9 +94.9 +56.2 +0.8 
June 2019 (n) 4439 872 1041 2435 
June 2020 (n) 11,395 5085 2686 6436 
Change (%) +156.7 +483.1 +158.0 +164.3 
July 2019 (n) 5110 967 1188 3086 
July 2020 (n) 8664 3247 2305 5085 
Change (%) +69.5 +235.8 +94.0 +64.8  
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laboratory is affiliated with, started a dedicated COVID-19 inpatient 
facility which further enhanced test requisition flow. This establishment 
alongside the tele-clinics improved routine patient inflow and the surge 
in test requests was evident. 
The highest number of active cases in Pakistan were recorded in 
June, which is in agreement with our data as an average of +240.5% 
hike in prognostic biomarkers test utilization was noted, which was 
significantly higher than the previous three months of 2020. Compared 
to the other three prognostic markers, significantly higher utility of LDH 
was noted. LDH is a cytoplasmic glycolytic enzyme found in almost 
every tissue, and its elevation generally indicates tissue damage. The 
role of elevated LDH has been previously well established in patients 
infected with MERS-CoV, H7N9, and H5N1 [13]. It has been widely 
accepted as an independent predictor of mortality for patients with se-
vere acute respiratory syndrome and H1N1 infection [14]. Its previous 
strong association with prognosis in acute respiratory distress syn-
dromes could be one reason for the increased requisition by physicians. 
On further evaluation, the number of requisitions declined signifi-
cantly during July compared to June 2020. This trend is in line with the 
COVID-19 country statistics, as Pakistan demonstrated a flattening of 
the disease curve in July 2020 [15]. 
The total specimen count in 2020 was lower during the peak 
pandemic months, a major contributor being lock down and movement 
restrictions. Even though, the hospital conceived a recovery plan for 
medical and surgical services and switched from ‘crisis mode’ to ‘back to 
usual’ the overall volumes remained low compared to the time span of 
2019 for the duration of this study. The potential reasons being the 
apprehensions of the patients and their families alongside the fear of 
contracting the virus from visiting medical and diagnostic facilities, 
while waiting in patient areas or being exposed while being treated, that 
have not been adequately alleviated despite the plateau in the number of 
cases. Subsequently, a significant drop in the overall routine biochem-
ical test requisitions, while on the other, a rapid surge in the test requests 
for the COVID-19 prognostic biomarkers was evident as shown by this 
study. 
Several guidelines were issued in response to pandemic preparedness 
that primarily focused on containment, treatment and diagnostic mo-
dalities. Meanwhile, there was also a dire need for early risk stratifica-
tion systems and biomarkers to predict disease progression and to 
identify high-risk patients at an early stage of the infection. During the 
COVID 19 pandemic while there was a significant reduction in overall 
laboratory requisitions owing to reduction in out-patient clinics and 
elective procedures, a significant increase in utilization of laboratory 
services was seen for C-RP, PCT, LDH and Ferritin. This elevated trend of 
prognostic biomarkers requisitions showed that while much was un-
known about the course of COVID-19 disease, the clinicians utilized 
some of the lessons learnt from previous experiences and knowledge of 
MERS-CoV, H7N9, and H5N1 and as more details regarding COVID 
clinical course, pathologies and possible useful interventions emerged in 
literature, clinicians utilized the laboratory services to good effect. This 
approach can optimize management goals, and overcome the shortage 
of medical and material resources which was particularly evident amidst 
this global emergency. As identification of reliable outcome predictors 
in COVID-19 is of paramount importance for improving patient’s man-
agement, while this specific objective was beyond the scope of this 
study, various studies have shown improved outcome, based on the 
Fig. 1. A comparison of COVID-19 prognostic biomarkers volumes for March to July in 2019 and 2020.  
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prognostic utility of abnormal inflammatory and organ injury circu-
lating biomarkers [16,17]. 
There were certain limitations of this study, as the evaluation of 
patients’ information/database was not performed, this study cannot 
demarcate between tests requisitions specifically pertaining to COVID- 
19 proven cases and those requested in routine clinical care of other 
disorders. 
5. Conclusion 
As the data on the use of selective biomarkers becomes available 
which showed more affective patient management and improved out-
comes, it has now become a standard practice to test for these prognostic 
biomarkers once a patient tests positive for COVID-19. Clinical labora-
tories should be prepared for the optimal inventory management in the 
pandemic era owing to the varying trend of biomarkers utilizations, as 
well as potential interruption of international trade. Moreover, delayed 
health care requirements are further expected to increase the work flow 
to the hospitals acutely as the restrictions are lifted. Therefore, the na-
tional case statistics should be carefully followed and resources of both 
personnel and materials should be pre-planned by the laboratory 
stakeholders. 
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